Clinical Trials for Bladder Cancer
260 bladder cancer trials indexed, 124 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Bladder Cancer
Bladder cancer is a disease where abnormal cells grow uncontrollably in the bladder lining. The bladder is a hollow organ in the lower abdomen that stores urine before it leaves the body. Most bladder cancers start in the urothelial cells, which line the inside of the bladder. These cancers can invade deeper layers of the bladder wall or spread to other organs if untreated. Doctors diagnose bladder cancer through a combination of urine tests, cystoscopy (using a camera to look inside the bladder), and biopsies to examine tissue samples under a microscope. Imaging tests like CT scans or MRIs may also help determine the cancer’s extent.
Common symptoms of bladder cancer include blood in the urine, frequent urination, pain during urination, and pelvic pain. These symptoms often prompt people to seek medical advice. Bladder cancer usually affects older adults, with most cases diagnosed in people over age 55. Men are about three to four times more likely to develop bladder cancer than women. Risk factors include smoking, exposure to certain industrial chemicals, chronic bladder inflammation, and a family history of the disease. Smoking is the most significant risk factor and accounts for nearly half of all bladder cancer cases.
Bladder cancer is a serious health concern worldwide. It is the sixth most common cancer in the United States, with an estimated 81,000 new cases diagnosed annually. The disease also causes about 17,000 deaths each year in the U.S. alone. Beyond health, bladder cancer places a considerable economic burden on healthcare systems due to frequent surveillance and treatment needs. Early detection improves outcomes, but the disease’s tendency to recur means ongoing monitoring is essential. Understanding bladder cancer helps highlight why research and improved treatments remain important for patients and society.
The Bladder Cancer Treatment Landscape
The first-line treatment for bladder cancer depends on the stage and grade of the tumor. Non-muscle invasive bladder cancer (NMIBC), which is confined to the bladder lining, is often treated with transurethral resection of the bladder tumor (TURBT) followed by intravesical therapy. Intravesical therapy involves placing drugs directly into the bladder to reduce recurrence risk. Bacillus Calmette-Guerin (BCG), a type of immunotherapy, is commonly used for high-risk NMIBC. For muscle-invasive bladder cancer (MIBC), treatment typically involves radical cystectomy (removal of the bladder) often combined with chemotherapy before or after surgery. Radiation therapy may be an option for those who cannot undergo surgery.
For patients whose cancer returns or progresses after first-line treatment, second- and third-line options include systemic therapies. Chemotherapy regimens often use platinum-based drugs such as cisplatin or carboplatin. Immunotherapy with immune checkpoint inhibitors targeting PD-1 or PD-L1 proteins has become an important option, especially for advanced or metastatic bladder cancer. Drugs like atezolizumab and pembrolizumab have been approved for these settings. Other treatments include targeted therapies and antibody-drug conjugates, which deliver chemotherapy directly to cancer cells. However, these options are generally considered after initial treatments have failed or if the cancer is not operable.
Despite these treatments, significant gaps remain. Some patients respond poorly to chemotherapy or immunotherapy, and resistance can develop over time. Side effects from treatments such as fatigue, infections, and bladder irritation can impact quality of life. Additionally, there is a need for better therapies for advanced bladder cancer and for those who cannot tolerate standard treatments. Research is focused on improving response rates, reducing side effects, and finding new drug combinations. Clinical trials play a key role in testing these new approaches to address current limitations.
Why Clinical Trials Matter for Bladder Cancer
Clinical trials offer patients with bladder cancer opportunities to access new treatments that are not yet widely available. These studies also provide closer monitoring by healthcare teams and contribute valuable information to medical science. Currently, there are about 260 bladder cancer clinical trials listed on ClinicalTrials.gov, with 124 actively recruiting participants. This variety of trials includes testing new drugs, combinations, and treatment strategies aimed at improving outcomes. Participation can be especially important for patients with advanced disease or those who have limited options after standard treatments.
It is important to understand the risks involved in clinical trials. New treatments may not work better than existing ones, and some patients may receive a placebo or standard treatment instead of the experimental drug. Additional clinic visits and tests required by trials can also be time-consuming and may cause extra stress. Side effects from investigational treatments are possible and may be unknown at the start of the study. Patients should discuss these factors carefully with their healthcare providers before enrolling in a trial.
Clinical trials for bladder cancer are sponsored by various organizations, including academic institutions, pharmaceutical companies, and cooperative groups that work together to conduct research. ClinicalTrials.gov serves as a central registry where these studies are listed, helping patients and doctors find trials that match specific conditions and locations. This transparency supports informed decisions and helps advance bladder cancer treatment by sharing information on ongoing research efforts worldwide.
What to Look for in a Bladder Cancer Clinical Trial
Clinical trials for bladder cancer are organized into phases that show the progress of testing a treatment. Phase 1 trials focus on safety and finding the right dose. Phase 2 trials look at how well the treatment works and continue to check safety. Phase 3 trials compare the new treatment to standard care to see if it offers any benefits. Phase 4 trials happen after a treatment is approved to monitor long-term effects. For bladder cancer, there are currently 81 trials in Phase 1, 66 in Phase 2, 38 in Phase 3, and 25 with unknown phase status, showing that many studies are still in early stages.
When joining a bladder cancer trial, patients must meet specific inclusion criteria. These usually include age limits, often adults 18 years or older. Prior treatments are considered, such as whether the patient has had chemotherapy or surgery before. Some trials require certain biomarkers, which are biological signs found in the tumor or blood. Staging of the cancer, which describes how advanced it is, is also important. Finally, the duration of the disease or time since diagnosis can affect eligibility, as some studies focus on newly diagnosed patients while others include those with recurrent cancer.
Exclusion criteria are just as important because they protect patient safety and ensure clear study results. Patients with other serious health problems, called comorbidities, might be excluded if these conditions could interfere with the treatment or increase risks. Drug interactions are also a concern; patients taking certain medications might not be eligible. Safety thresholds such as kidney or liver function tests play a role, too. These criteria help researchers avoid complications and make sure the treatment is tested in the right group of people.
From a patient perspective, practical factors matter when considering a clinical trial. The length of the trial, which can range from a few months to several years, affects commitment. The schedule of visits to the clinic for treatments, tests, or scans should fit with the patient’s lifestyle. Travel distance and costs may also be a concern. It is helpful to ask the research team specific questions such as: What are the possible side effects? How often will I need to visit the clinic? What happens if I want to leave the trial early? Will the treatment be covered by insurance or the study?
Primary Sources and Further Reading
For patients and caregivers seeking more information about bladder cancer and clinical trials, trusted sources provide detailed and up-to-date content. These resources can help you understand the disease, treatment options, and how to participate in research studies. Below are some recommended websites to explore further.
- National Cancer Institute: Bladder Cancer
- MedlinePlus: Bladder Cancer
- ClinicalTrials.gov: Bladder Cancer Trials
- Centers for Disease Control and Prevention: Bladder Cancer
Latest Research and Emerging Treatments for Bladder Cancer (2026)
Bladder cancer research in 2026 includes several Phase 3 trials testing new drugs and treatment strategies. One important area is immune checkpoint therapy, which helps the immune system recognize and attack cancer cells. A trial sponsored by the Alliance for Clinical Trials in Oncology is studying different treatment lengths using drugs like pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab (NCT04637594). The goal is to find out if stopping treatment after about a year works as well as continuing longer. This could reduce side effects and lower treatment costs for patients with advanced bladder cancer.
Another study is testing a combination of immunotherapy and chemotherapy before surgery, followed by immunotherapy alone, for muscle-invasive bladder cancer. This trial uses durvalumab with gemcitabine and cisplatin (NCT03732677). Chemotherapy kills cancer cells directly, while immunotherapy helps the immune system fight the cancer. This approach aims to improve survival rates for patients facing this aggressive form of bladder cancer.
For patients with high-risk non-muscle invasive bladder cancer who have not had BCG treatment, a Phase 3 trial is comparing TAR-200, a device that delivers treatment directly into the bladder, alone or with cetrelimab, an immune checkpoint inhibitor, against standard BCG therapy (NCT05714202). This research could offer new bladder cancer treatment options that might be easier to tolerate or more effective. These studies reflect ongoing efforts to find new drugs for bladder cancer that improve outcomes and quality of life for patients in 2026.
Frequently asked questions about Bladder Cancer trials
How do I find Bladder Cancer clinical trials?
The authoritative source for Bladder Cancer clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 260 bladder cancer studies are currently indexed. You can search by entering "bladder cancer" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new bladder cancer trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Bladder Cancer trials in?
Across the 260 bladder cancer trials TrialsAlert indexes, the most common phase is Phase 1. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Bladder Cancer clinical trials are currently recruiting?
As of the latest scan, 124 bladder cancer trials have a "Recruiting" status on ClinicalTrials.gov, out of 260 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting bladder cancer trial matches their tracked condition.
Stay informed about bladder cancer research
Get a weekly briefing with the trials that matter most.